Casirivimab + Imdevimab
Information about Casirivimab + Imdevimab
Casirivimab + Imdevimab Uses
Casirivimab+Imdevimab is used in the treatment of Coronavirus disease (COVID-19).
How Casirivimab + Imdevimab works
Casirivimab + Imdevimab is a combination of two human immunoglobulins G-1 (IgG1), neutralizing monoclonal antibodies, that bind at different sites on the spike protein of SARS-CoV-2, the virus that causes COVID-19. This unique binding mechanism, developed using recombinant DNA technology, is equally effective against the existing as well as newer emerging variants and prevents the virus from attaching to the human cell receptors.
Common side effects of Casirivimab + Imdevimab
Injection site reactions (pain, swelling, redness)
Available Medicine for Casirivimab + Imdevimab
Casirivimab & ImdevimabCipla Ltd
₹1195001 variant(s)
RonapreveCipla Ltd
₹1195001 variant(s)
Expert advice for Casirivimab + Imdevimab
- Casirivimab + Imdevimab, a monoclonal antibody cocktail therapy, is used to treat mild to moderate symptoms of COVID-19 in non-hospitalized adults and adolescents aged 12 years and older, who weigh at least 40 kg.
- The use of monoclonal antibodies is not indicated in severe hospitalized cases of COVID-19 or in those who require oxygen therapy.
- Even after the treatment, you should continue to practice (COVID)-appropriate behavior such as wearing a mask, social distancing, avoiding sharing personal items, and frequent handwashing.
- Before taking this antibody cocktail therapy, inform your doctor if you have any underlying medical conditions like diabetes, heart disease, high blood pressure, kidney disease, asthma, etc.
- Patients should be monitored during treatment and at least one hour after the completion of the infusion.
- Severe allergic reactions might happen during and after the use of monoclonal antibodies. Inform your doctor or nurse immediately if you experience shortness of breath, rapid or slow heart rate, chest pain, swelling of the face or lips, sweating.